SPONSOR
InSilico Medicine Hong Kong Limited
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Conditions studied: Advanced Solid TumorsRelapsed/Refractory B-cell LymphomaIdiopathic Pulmonary Fibrosis (IPF)
InSilico Medicine Hong Kong Limited is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma, Idiopathic Pulmonary Fibrosis (IPF).
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — InSilico Medicine Hong Kong Limited
How many clinical trials has InSilico Medicine Hong Kong Limited sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by InSilico Medicine Hong Kong Limited, of which 2 are actively recruiting participants. These trials cover conditions including Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma, Idiopathic Pulmonary Fibrosis (IPF). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does InSilico Medicine Hong Kong Limited research focus on?
InSilico Medicine Hong Kong Limited clinical trials span Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma, Idiopathic Pulmonary Fibrosis (IPF). The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a InSilico Medicine Hong Kong Limited clinical trial?
To participate in a InSilico Medicine Hong Kong Limited trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all InSilico Medicine Hong Kong Limited trials with current recruitment status updated daily.
Clinical Trials by InSilico Medicine Hong Kong Limited
NCT06445517 Phase 1
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Advanced Solid Tumors
NCT05975983 Phase 2
Recruiting
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology